Upregulation of putaminal dopamine D2 receptors in early Parkinson's disease: a comparative PET study with [11C] raclopride and [11C]N-methylspiperone.
暂无分享,去创建一个
V Kaasinen | J O Rinne | K. Någren | V. Oikonen | J. Rinne | H. Ruottinen | V. Kaasinen | P. Lehikoinen | V Oikonen | K Någren | P Lehikoinen | H M Ruottinen | Juha O. Rinne | Kjell Någren
[1] J. Rinne,et al. Positron emission tomography demonstrates dopamine D2 receptor supersensitivity in the striatum of patients with early Parkinson's disease , 1990, Movement disorders : official journal of the Movement Disorder Society.
[2] Ulla Ruotsalainen,et al. Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [11C]raclopride , 1995, Journal of the Neurological Sciences.
[3] S. Fahn. Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale , 1987 .
[4] K. L. Leenders,et al. Unilateral MPTP lesion in a rhesus monkey: effects on the striatal dopaminergic system measured in vivo with PET using various novel tracers , 1988, Brain Research.
[5] C. Pelizzari,et al. Accurate Three‐Dimensional Registration of CT, PET, and/or MR Images of the Brain , 1989, Journal of computer assisted tomography.
[6] G. Antoni,et al. The synthesis of 1-11C-labelled ethyl, propyl, butyl and isobutyl iodides and examples of alkylation reactions , 1986 .
[7] D. Wong,et al. Effects of endogenous dopamine on kinetics of [3H]N‐methylspiperone and [3H]raclopride binding in the rat brain , 1991, Synapse.
[8] P. Hartvig,et al. Dopamine receptor properties in Parkinson's disease and Huntington's chorea evaluated by positron emission tomography using 11C‐N‐methyl‐spiperone , 1987, Acta neurologica Scandinavica.
[9] A. Bonnet,et al. [The Unified Parkinson's Disease Rating Scale]. , 2000, Revue neurologique.
[10] J S Fowler,et al. Striatal binding of the PET ligand 11C‐raclopride is altered by drugs that modify synaptic dopamine levels , 1993, Synapse.
[11] A. Antonini,et al. [11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease , 1994, Neurology.
[12] K. Någren,et al. Improved synthesis of some commonly used PET radioligands by the use of [11C]methyl triflate. , 1995, Nuclear medicine and biology.
[13] S. Snyder,et al. Dopamine receptor binding enhancement accompanies lesion-induced behavioral supersensitivity. , 1977, Science.
[14] U Ruotsalainen,et al. PET study on striatal dopamine D2 receptor changes during the progression of early parkinson's disease , 1993, Movement disorders : official journal of the Movement Disorder Society.
[15] J M Links,et al. 3H-3-N-methylspiperone labels D2 dopamine receptors in basal ganglia and S2 serotonin receptors in cerebral cortex , 1986, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[16] M. Hoehn,et al. Parkinsonism , 1967, Neurology.
[17] C. Halldin,et al. A comparative PET-study of five carbon-11 or fluorine-18 labelled salicylamides. Preparation and in vitro dopamine D-2 receptor binding. , 1991, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.
[18] C. Patlak,et al. Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data. Generalizations , 1985, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[19] U Ruotsalainen,et al. Decrease in Human Striatal Dopamine D2 Receptor Density with Age: A PET Study with [11C]Raclopride , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[20] K. Leenders,et al. Comparison of 123I‐IBZM SPECT and 11C‐raclopride PET findings in patients with parkinsonism , 1994, Nuclear medicine communications.
[21] C S Patlak,et al. Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data , 1983, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[22] K. Någren,et al. PET demonstrates different behaviour of striatal dopamine D‐1 and D‐2 receptors in early Parkinson's disease , 1990, Journal of neuroscience research.
[23] O. Hornykiewicz,et al. Receptor basis for dopaminergic supersensitivity in Parkinson's disease , 1978, Nature.
[24] C. Marsden,et al. Recent Developments in Parkinson's Disease , 1986 .
[25] Richard S. J. Frackowiak,et al. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C‐raclopride and positron emission tomography , 1992, Annals of neurology.
[26] P. Seeman,et al. Endogenous dopamine lowers the dopamine D2 receptor density as measured by [3H]raclopride: Implications for positron emission tomography of the human brain , 1989, Synapse.
[27] Michael J. Adam,et al. Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease , 1985, Nature.
[28] M. Raichle,et al. MPTP‐induced up‐regulation of in vivo dopaminergic radioligand‐receptor binding in humans , 1987, Neurology.
[29] N. Volkow,et al. Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[30] C. Halldin,et al. Comparison of the In Vitro Receptor Binding Properties of N‐[3H]Methylspiperone and [3H]Raclopride to Rat and Human Brain Membranes , 1990, Journal of neurochemistry.
[31] R S Frackowiak,et al. Asymmetrical pre-synaptic and post-synpatic changes in the striatal dopamine projection in dopa naïve parkinsonism. Diagnostic implications of the D2 receptor status. , 1993, Brain : a journal of neurology.